Literature DB >> 33032999

Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015.

Bryant R England1,2, Punyasha Roul3, Yangyuna Yang3, Harlan Sayles4, Fang Yu4, Kaleb Michaud3,5, Fenglong Xie6, Jeffrey R Curtis6, Ted R Mikuls3,2.   

Abstract

OBJECTIVES: To compare the onset and trajectory of multimorbidity between individuals with and without rheumatoid arthritis (RA).
METHODS: A matched, retrospective cohort study was completed in a large, US commercial insurance database (MarketScan) from 2006 to 2015. Using validated algorithms, patients with RA (overall and incident) were age-matched and sex-matched to patients without RA. Diagnostic codes for 44 preidentified chronic conditions were selected to determine the presence (≥2 conditions) and burden (count) of multimorbidity. Cross-sectional comparisons were completed using the overall RA cohort and conditional logistic and negative binomial regression models. Trajectories of multimorbidity were assessed within the incident RA subcohort using generalised estimating equations.
RESULTS: The overall cohort (n=277 782) and incident subcohort (n=61 124) were female predominant (76.5%, 74.1%) with a mean age of 55.6 years and 54.5 years, respectively. The cross-sectional prevalence (OR 2.29, 95% CI 2.25 to 2.34) and burden (ratio of conditions 1.68, 95% CI 1.66 to 1.70) of multimorbidity were significantly higher in RA than non-RA in the overall cohort. Within the incident RA cohort, patients with RA had more chronic conditions than non-RA (β 1.13, 95% CI 1.10 to 1.17), and the rate of accruing chronic conditions was significantly higher in RA compared with non-RA (RA × follow-up year, β 0.21, 95% CI 0.20 to 0.21, p<0.001). Results were similar when including the pre-RA period and in several sensitivity analyses.
CONCLUSIONS: Multimorbidity is highly prevalent in RA and progresses more rapidly in patients with RA than in patients without RA during and immediately following RA onset. Therefore, multimorbidity should be aggressively identified and targeted early in the RA disease course. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; epidemiology; health care; outcome assessment; rheumatoid

Mesh:

Year:  2020        PMID: 33032999     DOI: 10.1136/annrheumdis-2020-218282

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.

Authors:  Alessandro Giollo; Giovanni Cioffi; Federica Ognibeni; Giovanni Orsolini; Andrea Dalbeni; Riccardo Bixio; Giovanni Adami; Angelo Fassio; Luca Idolazzi; Davide Gatti; Maurizio Rossini; Ombretta Viapiana
Journal:  Arthritis Res Ther       Date:  2021-06-03       Impact factor: 5.156

2.  Multimorbidity Burden in Rheumatoid Arthritis: A Population-based Cohort Study.

Authors:  Tina M Gunderson; Elena Myasoedova; John M Davis; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

3.  Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.

Authors:  Bryant R England; Huifeng Yun; Lang Chen; Jared Vanderbleek; Kaleb Michaud; Ted R Mikuls; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-08-02       Impact factor: 5.178

4.  Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Tina M Gunderson; Hayley J Dykhoff; Elena Myasoedova; Elizabeth J Atkinson; Vanessa L Kronzer; Caitrin M Coffey; John M Davis Iii
Journal:  RMD Open       Date:  2022-01

5.  Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?

Authors:  Amanda D Busby; James Wason; Arthur G Pratt; Adam Young; John D Isaacs; Elena Nikiphorou
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.